Tumor-bearing mice were divided into monotherapy treatment groups to receive 200 μg injections of anti-PD-1, anti-LAG-3, or anti-TIM-3 mAbs, or IgG isotype control. The gene discussed is HAVCR2; the disease is neoplasm.